What will 2015 look like for pharma?
This article was originally published in Scrip
With the New Year upon us, and with our recent efforts at scrying yet be refuted (see Why Pfizer won't come back for AstraZeneca and Why wait for accountants? Get pharma's 2014 Top 20 now), this seems like the perfect time for Scrip's renowned editorial team and regular contributors to continue riding the future-gazing wave and share their expectations for 2015.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.